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Population-Based Cohort Studies:
Still Relevant?
Paul Sorlie, PHD, Gina S. Wei, MD, MPH
Bethesda, Maryland
This commentary discusses the question whether observational epidemiology studies using a population-based cohort design continue
to make an impact on the prevention and treatment of cardiovascular disease. Although these studies are large and comprehensive,
have they advanced from the early recognition of traditional risk factors to become relevant in the current complex research environ-
ment? Five themes are discussed: 1) their role in scientific discovery, including in the context of clinical trials’ role in interventional re-
search; 2) their value in encompassing diverse ethnic and age groups to remain relevant to the changing diversity of the United States;
3) the research potential of combining these datasets into large consortia; 4) the ability to use advances in biomedical research tech-
nologies; and 5) the recognition that these are national resources that allow outside research community to analyze the collected data
and to originate novel ancillary studies. The National Heart, Lung, and Blood Institute longitudinal cohort studies offer opportunities that
hold great promise in improving evaluation of personal risk, identifying mechanisms of disease, and directing potential targets for be-
havior and medical interventions. (J Am Coll Cardiol 2011;58:2010–3) © 2011 by the American College of Cardiology Foundationi
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fAre observational epidemiology studies using apopulation-based cohort design still relevant?More specifically, do they make any significant
mpact on the prevention and treatment of cardiovascular
isease? Population-based cohort studies are a specific
ategory of epidemiology studies in which a defined popu-
ation is followed up and observed longitudinally to assess
xposure and outcome relationships (1). Some critics may
rgue that such studies have yielded little clinical impact
ecently—unlike decades ago when they helped uncover
ajor cardiovascular risk factors such as smoking, hyperten-
ion, and dyslipidemia (2). In contrast, randomized control
rials (RCTs) continue to make headlines, and the growing
se of electronic medical records seem to offer abundant
romises for research opportunities (3). Some may even
lame observational studies for leading the public astray. A
ell-known example is hormone “replacement” therapy, of
hich the beneficial effects identified in several observa-
ional cohort studies were later refuted by the Women’s
From the Epidemiology Branch, Prevention and Population Sciences Program,
Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute,
Bethesda, Maryland. Both authors have reported that they have no relationshipss
relevant to the contents of this paper to disclose.
Manuscript received May 3, 2011; accepted August 9, 2011.ealth Initiative; this then led to extensive investigations to
xplain the differences between the observational and trials
esults (4).
The RCT, despite its limitations, is the gold-standard
esearch method for determining the effectiveness of clinical
nterventions; nevertheless, population-based cohort studies
re still extremely relevant for other research purposes, such
s scientific discovery, informing the design of RCTs, and
ssessing effects of harmful exposures. Table 1 provides
xamples of the roles of observational cohort studies in
esearch discovery, as well as clinical trials’ roles in testing
nterventions. In general, although RCTs can test interven-
ions in more controlled environments, the research ques-
ions are typically intentionally focused—hence, generaliz-
bility may be restricted to narrowly defined populations. In
ontrast, observational cohort studies are established with
he capacity to address a wide range of research topics that
an be generalized to a community or an even broader
opulation. Aside from discovery, cohort studies can also be
sed to inform RCT designs. Hypothesis-generating dis-
overies from observational cohort studies are 1 source for
pawning research ideas for RCTs. They further provide
undamental data on disease rates to help estimate the trials’
ample-size requirements. Observational studies are also
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November 1, 2011:2010–3 Are Epidemiology Studies Still Relevant?critical when RCTs would be considered unethical, partic-
ularly when studying a potentially harmful exposure. For
example, given the known damaging effects of second-hand
smoke on the lung, observational studies were relied on to
identify whether it increased the risk for coronary heart
disease. Subsequent observational data that followed the
implementation of smoking bans have further shown an
ensuing decreased rate of heart attacks (5).
It is worth emphasizing the role of population-based
cohort studies in scientific discovery, particularly in unearth-
ing emergent risk factors and understanding the genetic and
biological basis of cardiovascular diseases. Some may argue
that the identification of cardiovascular risk factors is already
complete; however, this statement does not take into ac-
count that behavioral, social, and environmental exposure
patterns continue to evolve, and our ability to measure them
continues to improve. Additionally, a better understanding
of pathogenesis is relevant to improve translational research
for developing new therapeutics. The electronic medical
records are limited in these capacities, although they cer-
tainly hold great promises in other arenas, including health
services and outcomes research, post-market surveillance of
drug safety, and even nationwide disease surveillance. Med-
ical care databases are generally designed as either claims
data or clinical records, but in all cases reflect existing
clinical practices; these electronic medical record databases
do not include the novel bioassays or medical imaging
required for innovative research purposes (6). In contrast,
cohort studies can collect detailed data using measurement
tools that mirror current clinical practices and also cutting-
edge technologies that could lead to advances in health care.
The National Heart, Lung, and Blood Institute
(NHLBI) has supported large population-based cohort
studies in the United States beginning with the Framing-
ham Heart Study in the 1940s. These cohorts have been
initiated to remain relevant to the changing population
composition and the increasing sociocultural diversity of the
United States. Differences in health status among various
population groups are consistently confirmed by data on
variations in mortality (7). Current emphasis on under-
standing the genes and the environment, and their interac-
tive effects on disease, requires research in diverse popula-
tions and cultures. The NHLBI cohort studies listed in
Table 2 are drawn from many cultures, environments, and
locations. They examine exposures such as racial discrimi-
Table 1 Selected Examples of Research Roles of Population-Based
Discovery
Population-Based Cohort Studies
Discover potential environmental, behavioral, and biological factors
in relation to CVD
Identify novel risk factors that contribute independently to CVD
Establish CVD risk-prediction algorithms
Discover potential genetic influences on drug response
Identify interactive effects of biological, genetic, and environmental factors on CVD
Quantify burden and disparity of CVD in populationsCVD  cardiovascular disease.nation, acculturation, changing
life-style and food sources, eco-
nomic disadvantage, and the
built environment. In addition to
these listed studies, the NHLBI
has funded and continues to fund
investigator-initiated cohort stud-
ies, along with other epidemiology
studies such as community surveillance studies, disease regis-
tries, and follow-up of clinical trials (8–11).
Recently, the relevance of the traditional population-
based cohort studies has been challenged by the concept of
“mega-cohorts” that consist of several hundred thousands of
participants. The scientific rationale for such huge sample
sizes stems from the need to identify the numerous genetic
variants and their gene-gene and gene-environment inter-
actions for common yet complex disorders such as cardio-
vascular disease (12). The mega-cohorts could originate
from aggregated electronic medical records (e.g., HMO
[Health Maintenance Organization] Research Network), a
new identification of participants and collection of informa-
tion (e.g., UK Biobank), or consortia of existing cohorts
(e.g., the CHARGE [Cohorts for Heart and Aging Re-
search in Genomic Epidemiology] consortium) (13–15).
Studies that recruit and follow up very large populations de
novo would require, in the United States anyway, extremely
high operational costs (16). European studies can use their
extensive national health records systems to reduce these
costs considerably. Data collections that rely on existing
medical records, however, can be limited by the research
scope (i.e., data collected for medical care rather than for
research purposes) or by the unstandardized quality of the
information (17). An unanswered question is whether these
concerns are outweighed by the massive sample sizes.
Consortia of ongoing cohort studies can provide another
cost-efficient alternative to mega-cohorts. The studies listed
in Table 2 have been included in various consortia, and the
accumulated sample sizes can exceed 70,000 persons. These
existing consortia have adopted very conservative rules for
determining statistical significance, yet still discovered areas
of the genome associated with cardiovascular risk factors or
disease (18–20). However, as clearly described by the
National Human Genome Research Institute, the progres-
sion of “base pairs to bedside” is still in its early stages;
substantial research in the coming decades is expected
Abbreviations
and Acronyms
NHLBI  National Heart,
Lung, and Blood Institute
RCT  randomized control
trial
ort Studies and Clinical Trials: From Discovery to Intervention
Intervention
Randomized Clinical Trials
Test new interventions on environmental, behavioral, and
biological factors to prevent CVD
Determine optimal level of risk-factor management to prevent CVD
Test new interventions to treat established CVD
Test genetic influences on drug response
Compare treatments to identify optimal therapies for CVD
Test effectiveness of new diagnostic or screening modalitiesCoh
tudy of
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of clinical medicine can be realized (21). The balance of
cost, data validity, feasibility, and required sample size will
likely continue to frame the welcome ongoing discussions of
the role of mega-cohorts versus traditional population-based
cohorts.
To remain relevant in a technologically evolving world,
cohort studies should be able to capture data using advances
in biomedical research technologies. These past decades
have witnessed an explosion of discoveries of the genetic
complexity associated with human diseases and the molec-
ular signatures that describe underlying processes for health
and disease. The study of blood components has moved well
beyond the earliest measures of cholesterol to the most
complex measures of proteins and metabolites. The genetic
world has moved from assessing simple genetic character-
istics to genotyping a million or more single-nucleotide
polymorphisms, and recently to genomic sequencing. Many
large NHLBI cohort studies have readily incorporated these
measurements into their data collection. The use of nonin-
vasive technologies of ultrasound imaging, computerized
tomography, and magnetic resonance imaging have further
permitted cohort studies to assess disease process from the
healthy to subclinical state and to the manifestation of
clinical disease—all adding to their values as research
resources to more directly measure the processes leading to
disease.
To remain relevant to research needs, observational co-
hort studies must also allow access to their rich resources.
Their value is likely to increase as research funding becomes
more limited and demands for high-quality scientific data
rise. The primarily contract-based funding of the studies
listed in Table 2 support the infrastructure, recruitment,
examinations, follow-up, event identification and validation,
specimen storage, and statistical analysis. With this foun-
dation, these studies create opportunities for investigator-
initiated grants—either as a stand-alone project or as part of
a consortium—to add examination components, to use
Table 2 Large Population-Based Cohort Studies in the NHLBI Fund
Year of First
Examination Name of Study
1948 Framingham Heart Study White
1971 Framingham Heart Study–Offspring White
1985 Coronary Artery Risk Development in Young Adults White/blac
1987 Atherosclerosis Risk in Communities White/blac
1989 Cardiovascular Health Study White/blac
1989 Strong Heart Study American I
1991 Women’s Health Initiative* White (82%
2000 Jackson Heart Study Black
2000 Multi-Ethnic Study of Atherosclerosis† White/blac
2001 Strong Heart Study Family Study American I
2001 Genetics of Coronary Artery Disease in Alaska Natives Alaska nat
2002 Framingham Heart Study–Generation 3 White
2008 Hispanic Community Health Study/Study of Latinos Mexican/P
and Sou
*The Women’s Health Initiative initially had both an observational and a clinical trial component; the
participants (all other studies on this list recruited both male and female subjects). †The Multi-Ethnic S
cardiovascular disease.collected biological samples for new analytes or genotyping,and for additional statistical analyses. The listed cohort
studies often have 20 to 75 added ancillary studies, many
involving non–study investigators. Additionally, non–study
researchers can access data through an extensive data dis-
tribution process provided by the NHLBI. Phenotype data
are available through the NHLBI’s Biologic Specimen and
Data Repository Information Coordinating Center (22),
and the combined genetic and phenotypic data are accessi-
ble through the National Center for Biotechnology Infor-
mation’s Database of Genotypes and Phenotypes (23).
As the NHLBI looks to the future, its cohort studies will
continue to evolve by taking advantage of rapid advances in
research technology and adding (or ending) cohorts in
response to research needs, yet remain committed to max-
imizing research potential. The NHLBI population-based
cohort studies are national resources. They offer opportuni-
ties to evaluate countless scientific hypotheses to translate
bench research to both prevention and treatment, furthering
insight into the complex interaction of environment, behav-
iors, and genetics on cardiovascular disease. These oppor-
tunities hold great promise in improving evaluation of
personal risk, identifying mechanisms of disease, and direct-
ing potential targets for behavior and medical interventions.
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